Elliptic Laboratories A Debt/EBITDA
The Total Debt to EBITDA Ratio of Elliptic Laboratories A (ELABS.OL) as of Oct 25, 2026 is -0.18. In the previous year, Total Debt to EBITDA Ratio was 0.77 — a change of -123.73% (lower).
Get this data via API
Financial Data API
Debt/EBITDA
-0.18
YoY
-123.73%
Last updated:
The Elliptic Laboratories A Debt/EBITDA history
3 Years
10 Years
25 Years
Max
| YEAR | Debt/EBITDA | YoY |
|---|---|---|
| -0.18 | -123.73% | |
| 0.77 | -199.85% | |
| -0.77 | +87.12% | |
| -0.41 | -91.16% | |
| -4.66 | +48.81% | |
| -3.13 | -41.10% | |
| -5.32 | +255.96% | |
| -1.49 | +236.16% | |
| -0.44 | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Elliptic Laboratories A Stock analysis
Frequently Asked Questions about Elliptic Laboratories A stock
Total Debt to EBITDA Ratio of Elliptic Laboratories A is -0.18 in 2025.
Total Debt to EBITDA Ratio of Elliptic Laboratories A changed from 0.77 to -0.18, representing a -123.73% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Elliptic Laboratories A since 2006 – with annual values, charts, and detailed analysis.
Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.
A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Elliptic Laboratories A with sector peers and the industry average to assess whether it is attractive.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Leverage — Elliptic Laboratories A
All Key Metrics — Elliptic Laboratories A
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth